What is up you guys? Welcome to another edition of Controversial Thoughts. Happy Thanksgiving to everyone.

If you are listening to this on the day after Thanksgiving, I hope that you are spending time with friends and family that you got lots of organs in your diet over Thanksgiving that you are celebrating knows to tell November with us.

If you need more organs in your diet, check us out at heartandsoil.co.grassfed grass finished. We're generally raised organs and capsules.

We're going to fire starter back in the next few days before organs coming next week.

Immunomilk hopefully coming next week, heart of the warrior hopefully coming shortly after that. So lots of exciting things happening on the designated organ front at heart and soil.

This week's podcast was with Peter from Hyperlipid. Do not sleep on that podcast. Peter is brilliant and we dove deeply into the molecular mechanisms of polyunsaturative fats.

We're going to talk about the mitochondria and why creating inappropriate insulin sensitivity is a bad thing in humans. Now I want to talk more about COVID because coronavirus is on everyone's mind again.

And let's dig into it. So I wanted to talk about the vaccine in this video. My thoughts about the vaccine.

I've talked about this, what I've read about it and my thoughts and my concerns about it. So let's start with this. So back in July, there was a paper published in the New England Journal of Medicine.

I believe this is the Moderna pharmaceutical group because yes, it is because they're talking about MRA and M RNA 12, not 12 73, which encoded a stabilized prefusion SARS, COVID 2 spike protein.

So the first inclination that we got that we were going to get an MR and a vaccine. I'll explain what that is in a moment.

But this small trial of 45 healthy adults back in was published in July, August of 2020, looked promising. There certainly were some side effects.

And the second vaccination serum neutralizing activity was detected by two methods in all participants evaluated. Values generally similar to those in the upper half of the distribution of a panel of control, convalescent serum specimens.

So what they're saying is, hey, if we inject you with our M RNA, this is MRNA 12 73 from Moderna pharmaceuticals.

We'll talk a little bit about Pfizer in a moment. You you will get a response of antibodies or serum neutralizing activity, quote unquote similar to convalescent serum, those people who have been actually sick with the virus. Now they mentioned the adverse events that occurred in more than half of the dispense were fatigue, chills, headache, myalgia, pain at the injection sites, severe adverse against more common after the second vaccination.

So they used multiple doses 25 microgram, 100 microgram and I believe a 250 microgram group. And I'm not sure whether the protocol is going to have two vaccinations for people moving forward, but there were systemic adverse events in this small trial.

And more than half the group actually got some bad side effects, which isn't necessarily to be isn't necessarily surprising because you're injecting someone with an M RNA for for an viral protein.

Your immune system is going to turn on and your immune system is going to essentially fight a fragment of the virus and you are going to get cytokines, you may feel badly, but you are not going to have presumably a virulent viral particle in your body that is going to cause major adverse long term effects.

Interesting, right? It's an M RNA virus. It's the first one of its kind. We don't have any other mRNA viruses used in medicine now. So these will be interesting. Now the Pfizer vaccine is pretty similar.

So if you look at the Pfizer press release, it's much more recent. This is from November the 9th at 2020 and they had 45,538 participants. I don't think Moderna has gone back and done a bigger group. They may have.

And 42% having diverse backgrounds. They say they had no serious safety concerns. Safety and additional efficacy data continue to be collected. Okay. So there's still safety and efficacy data pending here.

Clinical trial to continue through the final analysis at 164 confirmed cases in order to collect further data and characterize the vaccines.

...